title: Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.
abstract: Evidence suggests the estrogens may play a role in various mental and neurodegenerative diseases. We review the evidence implicating estradiol in schizophrenia and Parkinson's disease. Epidemiologic and clinical studies on the effects of estrogens in schizophrenia are surveyed, and animal studies and in vitro models of the modulatory effects of estrogens on neurotransmitters associated with schizophrenia (i.e., dopamine, serotonin, glutamate) are reviewed. Epidemiologic and clinical data suggesting a role for estrogens in Parkinson's disease and in vivo and in vitro models demonstrating neuroprotective effects of estrogens are then examined. Despite the numerous animal studies on the effects of estrogens in the brain, clinical data are sparse and often contradictory. Compounds with more specific and potent estrogenic activity in the brain are required to further research efforts in this area. Possible candidates are the selective estrogen receptor modulators (SERMs), whose agonist or antagonist properties depend on the target tissue. The effects of various SERMs in the brain are reviewed, and our novel findings on the effects of SERMs on 5-HT2A receptors in the rat cortex and nucleus accumbens are presented. We suggest that drugs with estrogenic activity in the brain may have therapeutic potential, either by modulating brain neurotransmission or through neuroprotective activity.
authors.affiliation: Oncology and Molecular Endocrinology Research Centre, Faculté de pharmacie, Université Laval, Sainte-Foy, Que.
authors.forename: Michel
authors.initials: M
authors.lastname: Cyr
authors.forename: Frederic
authors.initials: F
authors.lastname: Calon
authors.forename: Marc
authors.initials: M
authors.lastname: Morissette
authors.forename: Thérèse
authors.initials: T
authors.lastname: Di Paolo
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D019208:Brain-Derived Neurotrophic Factor / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D006801:Humans; D009414:Nerve Growth Factors / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D051381:Rats; D018091:Receptors, AMPA / Q000187:drug effects; D011954:Receptors, Dopamine / Q000187:drug effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D004967:Estrogens; D009414:Nerve Growth Factors; D018091:Receptors, AMPA; D011954:Receptors, Dopamine; D016194:Receptors, N-Methyl-D-Aspartate; D011985:Receptors, Serotonin